An effective approach for targeting lymphoma and leukemia cell lines with a novel Tan-CAR (CD30/CD20) T cell

Abstract

Despite the success of single-target antigen CART therapy against CD19, there are certain limitations that need to be investigated properly to build a universal treatment for hematologic cancer. Other than CD19, there have been many reports on CD30 and CD20, which are also clinically relevant in different types of hematologic malignancies, but no reports have been published yet that target both antigens as bispecific targets on a single cell. Therefore, we developed a tandem receptor that targets dual antigens with a single receptor and likely reduces tumor marker escape mutations. In this study, we employed a gene editing strategy to disrupt TCRs and a target-specific integration of CAR receptors into T cells to develop a novel CAR model to address tumor-off-target limitations.

Keywords

CAR T cell therapy / third-generation CAR receptor / tandem-CAR / bispecific targets / CD20 / CD30 / CRISPR/CasS9

References

[1] Masopust D, Schenkel JM (2013) The integration of T cell migration, differentiation and function. Nat Rev Immunol 13: 309-320. https://doi.org/10.1038/nri3442

[2] Eshhar Z, Waks T, Gross G (2014) The emergence of T—bodies/CAR T cells. Cancer J 20: 123-126. https://doi.org/10.1097/PPO.0000000000000027

[3] Eshhar Z, Waks T, Bendavid A, et al. (2001) Functional expression of chimeric receptor genes in human T cells. J Immunol Methods 248: 67-76. https://doi.org/10.1016/S0022—1759(00)00343—4

[4] Posa MK, Singh J, Parveen S, et al. (2026) CAR T—cell therapy: A promising novel approach for treatment of cancer. Cancer Treat Res Commun 47: 101125. https://doi.org/10.1016/j.ctarc.2026.101125

[5] June CH, O’Connor RS, Kawalekar OU, et al. (2018) CAR T cell immunotherapy for human cancer. Science 359: 1361-1365. https://doi.org/10.1126/science.aar6711

[6] McGuirk J, Waller EK, Qayed M, et al. (2017) Building blocks for institutional preparation of CTL019 delivery. Cytotherapy 19: 1015-1024. https://doi.org/10.1016/j.jcyt.2017.06.001

[7] Tumaini B, Lee DW, Lin T, et al. (2013) Simplified process for the production of anti—CD19—CAR—engineered T cells. Cytotherapy 15: 14061415. https://doi.org/10.1016/j.jcyt.2013.06.003

[8] Qi Y, Zhao MF, Hu YX, et al. (2022) Efficacy and safety of CD19—specific CAR T cell—based therapy in B—cell acute lymphoblastic leukemia patients with CNSL. Blood 139: 3376-3386. https://doi.org/10.1182/blood.2021013733

[9] Maude SL, Laetsch TW, Buechner J, et al. (2018) Tisagenlecleucel in children and young adults with B—cell lymphoblastic leukemia. N Engl J Med 378: 439-448. https://doi.org/10.1056/NEJMoa1709866

[10] Zhao J, Song Y, Liu D (2019) Clinical trials of dual—target CAR T cells, donor—derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia. J Hematol Oncol 12: 1-11. https://doi.org/10.1186/s13045—019—0705—x

[11] Grada Z, Hegde M, Byrd T, et al. (2013) TanCAR: A novel bispecific chimeric antigen receptor for cancer immunotherapy. Mol Ther Nucleic Acids 2: e105. https://doi.org/10.1038/mtna.2013.32

[12] Ramos CA, Grover NS, Beaven AW, et al. (2020) Anti—CD30 CAR—T cell therapy in relapsed and refractory Hodgkin lymphoma. J Clin Oncol 38: 3794. https://doi.org/10.1200/JCO.20.01342

[13] Ramos CA, Ballard B, Zhang H, et al. (2017) Clinical and immunological responses after CD30—specific chimeric antigen receptor—redirected lymphocytes. J Clin Invest 127: 3462-3471. https://doi.org/10.1172/JCI94306

[14] Bhatt G, Maddocks K, Christian B (2016) CD30 and CD30—targeted therapies in Hodgkin lymphoma and other B cell lymphomas. Curr Hematol Malig Rep 11: 480-491. https://doi.org/10.1007/s11899—016—0345—y

[15] Mark E, Sutton M, Gru A (2022) Primary cutaneous anaplastic large—cell lymphoma with aberrant CD20 expression: Case report and review of the literature. Am Jo Dermatopathol 44: 971-978. https://doi.org/10.1097/DAD.0000000000002281

[16] Huang Y, Chen S, Wei R, et al. (2020) CD20—positive extranodal NK/T cell lymphoma: clinicopathologic and prognostic features. Virchows Arch 477: 873-883. https://doi.org/10.1007/s00428—020—02776—x

[17] Imai M, Jiang JG, Wu Z, et al. (2013) CD20—positive T—cell lymphoma involving bone marrow: Report of four cases. J Hematopathol 6: 201-205. https://doi.org/10.1007/s12308—013—0177—9

[18] Karube K, Kakimoto Y, Tonozuka Y, et al. (2021) The expression of CD30 and its clinico—pathologic significance in peripheral T—cell lymphomas. Expert Rev Hematol 14: 777-787. https://doi.org/10.1080/17474086.2021.1955344

[19] Onaindia A, Martínez N, Montes—Moreno S, et al. (2016) CD30 expression by B and T cells. Am J Sur Pathol 40: 378-385. https://doi.org/10.1097/PAS.0000000000000571

[20] Klimka A, Barth S, Matthey B, et al. (1999) An anti—CD30 single—chain Fv selected by phage display and fused to Pseudomonas exotoxin A (Ki—4 (scFv)—ETA’) is a potent immunotoxin against a Hodgkin—derived cell line. Br J Cancer 80: 1214-1222. https://doi.org/10.1038/sj.bjc.6690488

[21] Guercio M, Orlando D, Di Cecca S, et al. (2021) CD28.OX40 co—stimulatory combination is associated with long in vivo persistence and high activity of CAR. CD30 T cells. Haematologica 106: 987. https://doi.org/10.3324/haematol.2019.231183

[22] Shah NN, Johnson BD, Schneide D, et al. (2020) Bispecific anti—CD20, anti—CD19 CAR T cells for relapsed B cell malignancies: A phase 1 dose escalation and expansion trial. Nat Med 26: 1569-1575. https://doi.org/10.1038/s41591—020—1081—3

[23] Wu AM, Tan GJ, Sherman MA, et al. (2001) Multimerization of a chimeric anti—CD20 single—chain Fv—Fc fusion protein is mediated through variable domain exchange. Protein Eng 14: 1025-1033. https://doi.org/10.1093/protein/14.12.1025

[24] Guo Z, Tu S, Yu S, et al. (2021) Preclinical and clinical advances in dual‐target chimeric antigen receptor therapy for hematological malignancies. Cancer Sci 112: 1357-1368. https://doi.org/10.1111/cas.14799

[25] Zhang WY, Wang W, Guo YL, et al. (2016) Treatment of CD20—directed chimeric antigen receptor—modified T cells in patients with relapsed or refractory B—cell non—Hodgkin lymphoma: An early phase IIa trial report. Signal Transduction Targeted Ther 1: 1-9. https://doi.org/10.1038/sigtrans.2016.2

[26] Mohanty R, Manoswini M, Dhal AK, et al. (2022) In silico analysis of a novel protein in CAR T—cell therapy for the treatment of hematologic cancer through molecular modelling, docking, and dynamics approach. Comput Biol Med 151: 106285. https://doi.org/10.1016/j.compbiomed.2022.106285

[27] Jagannath S, Joseph N, Crivera C,et al. (2023) Component costs of CAR—T therapy in addition to treatment acquisition costs in patients with multiple myeloma. Oncol Ther 11: 263-275. https://doi.org/10.1007/s40487—023—00228—5

[28] Oh S, Mao X, Manfredo—Vieira S, et al. (2023) Precision targeting of autoantigen—specific B cells in muscle—specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells. Nat Biotechnol 41: 1229-1238. https://doi.org/10.1038/s41587—022—01637—z

[29] Shen CJ, Yang YX, Han EQ, et al. (2013) Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma. J Hematol Oncol 6: 1-7. https://doi.org/10.1186/1756—8722—6—33

[30] Gagelmann N, Ayuk F, Atanackovic D, et al. (2020) B cell maturation antigen‐specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma: A meta‐analysis. Eur J Haematol 104: 318-327.https://doi.org/10.1111/ejh.13380

[31] Pan J, Niu Q, Deng B, et al. (2019) CD22 CAR T—cell therapy in refractory or relapsed B acute lymphoblastic leukemia. Leukemia 33: 2854-2866. https://doi.org/10.1038/s41375—019—0488—7

[32] O'Hara M, Stashwick C, Haas AR, et al. (2016) Mesothelin as a target for chimeric antigen receptor—modified T cells as anticancer therapy. Immunotherapy 8: 449-460. https://doi.org/10.2217/imt.16.4

[33] Lam N, Finney R, Yang S, et al. (2021) Development of a Bicistronic anti—CD19/CD20 CAR construct including optimization to abrogate retroviral recombination events. Blood 138: 4808. https://doi.org/10.1016/j.omto.2023.07.001

[34] Wu J, Meng F, Cao Y, et al. (2021) Sequential CD19/22 CAR T—cell immunotherapy following autologous stem cell transplantation for central nervous system lymphoma. Blood Cancer J 11: 131. https://doi.org/10.1038/s41408—021—00523—2

[35] Schneider D, Xiong Y, Wu D, et al. (2021) Trispecific CD19—CD20—CD22—targeting duoCAR—T cells eliminate antigen—heterogeneous B cell tumors in preclinical models. Sci Transl Med 13: eabc6401. https://doi.org/10.1126/scitranslmed.abc6401

[36] Xue Y, Lai X, Li R, et al. (2021) CD19 and CD30 CAR T—cell immunotherapy for high—risk classical Hodgkin’s lymphoma. Front Oncol 10: 607362. https://doi.org/10.3389/fonc.2020.607362

[37] Uddin F, Rudin CM, Sen T (2020) CRISPR gene therapy: Applications, limitations, and implications for the future. Front Oncol 10: 1387. https://doi.org/10.3389/fonc.2020.01387

[38] Eyquem J, Mansilla—Soto J, Giavridis T, et al. (2017) Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature 543: 113-117. https://doi.org/10.1038/nature21405

[39] Sadeqi Nezhad M, Yazdanifar M, Abdollahpour—Alitappeh M, et al. (2021) Strengthening the CAR‐T cell therapeutic application using CRISPR/Cas9 technology. Biotechnol Bioeng 118: 3691-3705. https://doi.org/10.1002/bit.27889

[40] Manriquez—Roman C, Siegler EL, Kenderian SS (2021) CRISPR takes the front seat in CART—cell development. BioDrugs 35: 113-124. https://doi.org/10.1007/s40259—021—00473—y

[41] Ren J, Zhao Y (2017) Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9. Protein cell 8: 634-643. https://doi.org/10.1007/s13238—017—0410—x

[42] Xia AL, He QF, Wang JC, et al. (2019) Applications and advances of CRISPR—Cas9 in cancer immunotherapy. J Med Genet 56: 4-9. https://doi.org/10.1136/jmedgenet—2018—105422

[43] Hartmann S, Goncharova O, Portyanko A, et al. (2019) CD30 expression in neoplastic T cells of follicular T cell lymphoma is a helpful diagnostic tool in the differential diagnosis of Hodgkin lymphoma. Modern Pathology 32: 37-47. https://doi.org/10.1038/s41379—018—0108—5

[44] Greenbaum U, Mahadeo KM, Kebriaei P, et al. (2020) Chimeric antigen receptor T—cells in B—acute lymphoblastic leukemia: State of the art and future directions. Front Oncol 10. https://doi.org/10.3389/fonc.2020.01594

[45] Zhang S, Gu C, Huang L, et al. (2022) The third—generation anti—CD30 CAR T—cells specifically homing to the tumor and mediating powerful antitumor activity. Sci Rep 12: 10488. https://doi.org/10.1038/s41598—022—14523—0

[46] Iżykowska K, Rassek K, Korsak D, et al. (2020) Novel targeted therapies of T cell lymphomas. J Hematol Oncol 13: 1-38. https://doi.org/10.1186/s13045—020—01006—w

[47] Rafiq S, Hackett CS, Brentjens RJ (2020) Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol 17: 147-167. https://doi.org/10.1038/s41571—019—0297—y

[48] Cheng Z, Wei R, Ma Q, et al. (2018) In vivo expansion and antitumor activity of coinfused CD28—and 4—1BB—engineered CAR—T cells in patients with B cell leukemia. Mol Ther 26: 976-985. https://doi.org/10.1016/j.ymthe.2018.01.022

[49] Weinkove R, George P, Dasyam N, et al. (2019) Selecting costimulatory domains for chimeric antigen receptors: Functional and clinical considerations. Clin Transl Immunol 8: e1049. https://doi.org/10.1002/cti2.1049

[50] Shirasu N, Kuroki M (2012) Functional design of chimeric T—cell antigen receptors for adoptive immunotherapy of cancer: Architecture and outcomes. Anticancer Res 32: 2377-2383.